Uwe Zangemeister-Wittke

Prof. Uwe Zangemeister-Wittke


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JWJohannes Winkler
Johannes Winkler
PMPatricia Martin-Killias
Patricia Martin-Killias
APAndreas Plückthun
Andreas Plückthun
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke
Specific delivery to tumors and efficient cellular uptake of nucleic acids remain major challenges for gene-targeted cancer therapies. Here we report the use of a designed ankyrin repeat protein (DARPin) specific for the epithelial cell adhesion molecule (EpCAM) as a carrier for small interfering RNA (siRNA) complementary to the bcl-2 mRNA. For charge complexation of the siRNA, the DARPin was fused to a truncated human protamine-1 sequence. To increase the cell binding affinity and the amount of siRNA delivered into cells, DARPin dimers were generated and used as fusion proteins with protamine. All proteins expressed well in Escherichia coli in soluble form, yet, to remove tightly bound bacterial nucleic acids, they were purified under denaturing conditions by immobilized metal ion affinity chromatography, followed by refolding. The fusion proteins were capable of complexing four to five siRNA molecules per protamine, and fully retained the binding specificity for EpCAM as shown on MCF-7 breast carcinoma cells. In contrast to unspecific LipofectAMINE transfection, down-regulation of antiapoptotic bcl-2 using fusion protein complexed siRNA was strictly dependent on EpCAM binding and internalization. Inhibition of bcl-2 expression facilitated tumor cell apoptosis as shown by increased sensitivity to the anticancer agent doxorubicin. [Mol Cancer Ther 2009;8(9):2674–83]

11 November 2013 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MSManuel Simon
Manuel Simon
RFRaphael Frey
Raphael Frey
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke
APAndreas Plückthun
Andreas Plückthun

1 November 2020 in Journal of Controlled Release
Verified
Journal Article
Open access
FBFabian Brandl
Fabian Brandl
SBSarah Busslinger
Sarah Busslinger
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke
APAndreas Plückthun
Andreas Plückthun
Despite some approvals of antibody-drug conjugates for cancer therapy, their clinical success rate is unsatisfactory because of very small therapeutic windows, influenced by on-target and off-target toxicities of conjugate and liberated toxin. Additional formats with systematically investigated molecular parameters must therefore be explored to increase their therapeutic window. Here we focused on the effective molecular weight. To generate conjugates with exactly defined drug loads and tunable pharmacokinetics, we used Designed Ankyrin Repeat Proteins (DARPins), fused to unstructured polypeptides of different lengths, to produce proteins with any desired half-life, to identify those with the best efficacy. We generated an EpCAM-targeting DARPin-MMAF conjugate, fused to PAS or XTEN of different lengths, and a matched series of controls of a non-binding DARPin to account for the enhanced permeability and retention (EPR) effect, covering half-lives of minutes to 20.6 h in mice. All conjugates were produced at high purity, and demonstrated high specificity and cytotoxicity in human tumor cell cultures, with IC50 values in the low nM range, independent of the polypeptide type and length. Due to their more facile purification, the PASylated conjugates were tested in nude mice bearing HT29 tumor xenografts. Independent of their size, all PASylated conjugates were very well tolerated after repeated systemic administration of 300 nmol/kg. We found that the conjugates with intermediate size and half-life showed the strongest anti-tumor effects, and deduced that this effect is a compromise of serum half-life and diffusion within the tumor, as on-rates and affinities are essentially identical, with extravasation playing only a very minor role.

8 July 2015 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
HMHannes Merten
Hannes Merten
FBFabian Brandl
Fabian Brandl
APAndreas Plückthun
Andreas Plückthun
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke

1 July 2003
Verified
Journal Article
Closed access
CPClaudio Di Paolo
Claudio Di Paolo
JWJörg Willuda
Jörg Willuda
SKSusanne Kubetzko
Susanne Kubetzko
ILIkar Lauffer
Ikar Lauffer
DTDominique Tschudi
Dominique Tschudi
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke

1 August 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
FBFabian Brandl
Fabian Brandl
HMHannes Merten
Hannes Merten
MZMartina Zimmermann
Martina Zimmermann
MBMartin Béhé
Martin Béhé
UZUwe Zangemeister-Wittke
Uwe Zangemeister-Wittke
APAndreas Plückthun
Andreas Plückthun